Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.50 |
| ▸ | MGAM | O43451 | 2/20 | 0.50 |
| ▸ | SI | P14410 | 2/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.50 |
| ▸ | GRK6 | P43250 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449669 | 0.92 | MGAM (0.49) | GAAMGAMSIMGAM2GRK6 | |
| SCHEMBL6448909 | 0.86 | GRK6 (0.49) | GRK6RAB9ANPC1NR1H2NR1H3 | |
| SCHEMBL6448841 | 0.85 | GRK6 (0.47) | GAAGRK6KMT2AMEN1ALOX15 | |
| SCHEMBL6448635 | 0.83 | SMN1; SMN2 (0.55) | GAAMGAMSIMGAM2GRK6 | |
| SCHEMBL6456986 | 0.83 | GRK6 (0.46) | GRK6KMT2AMEN1ALOX15RAB9A | |
| SCHEMBL6452540 | 0.83 | IDO1 (0.44) | KMT2AMEN1ALOX15RAB9AMAPT | |
| SCHEMBL6460763 | 0.83 | TGFBR1 (0.41) | KMT2AMEN1ALOX15RAB9AMAPT | |
| SCHEMBL6452275 | 0.81 | MEN1 (0.39) | GAAMGAMSIMGAM2GRK6 | |
| SCHEMBL6453486 | 0.81 | ADORA2A (0.60) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6451523 | 0.80 | NR1H2 (0.65) | GRK6NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | GAA 519/4885MGAM 4379/4885SI 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.